Breast cancer immunotherapy: who may be eligible and which tests matter

Start with the stage and subtype

The term immunotherapy covers different approaches, but checkpoint inhibitors are the medicines most often meant in this breast cancer discussion. Their use depends on the cancer subtype and stage. Evidence for TNBC does not automatically establish the same role in hormone receptor-positive or HER2-positive disease.

Ask whether the proposal is a standard treatment for your setting or a clinical trial. The answer should include the exact medicine, combination and treatment goal. This gives you a concrete basis for comparing it with the alternative plan.

Sources and references: [1] [2]

In early TNBC, the plan includes surgery

For selected high-risk early TNBC, pembrolizumab is combined with chemotherapy before surgery and then continued in the postoperative plan. The treatment is selected by the early-disease risk setting, without applying the same PD-L1 selection rule used for metastatic TNBC.

Ask why your stage and risk fit the regimen and how response will be checked. The surgical pathology still matters for the rest of treatment. A good scan response does not independently settle the need for surgery or the remaining medicines.

Sources and references: [1] [2]

In advanced TNBC, PD-L1 can change the choice

For selected previously untreated advanced TNBC, pembrolizumab with chemotherapy has an established role when PD-L1 combined positive score is at least 10. The team must also consider the previous treatment history and whether the clinical setting matches the evidence.

Bring the complete PD-L1 report, including the assay and scoring method. A positive label without those details may not answer the treatment question. Ask whether the sample is suitable and whether another test would materially change the recommendation.

Sources and references: [1]

When a different biomarker may matter

Rare biomarker findings can sometimes support an immunotherapy discussion under a tumor-agnostic indication or a clinical trial. These are distinct from routine PD-L1 selection in TNBC. A broad molecular report needs interpretation of the exact finding and applicable treatment setting.

Ask which result is actionable and what evidence supports acting on it now. If no relevant biomarker or indication is present, other systemic therapies may offer a clearer treatment path. Testing is most useful when it can resolve a specific choice.

Sources and references: [1] [2]

Review immune health before starting

A history of autoimmune illness, immune-suppressing treatment or an organ transplant can affect the safety discussion. The oncology team may need input from another specialist. Previous immune-related toxicity from cancer treatment also matters.

Bring a list of diagnoses and current medicines, including steroids. Ask how the proposed treatment could affect the existing condition and what alternative would be considered. The aim is to compare realistic benefits and risks for your health, not simply to qualify for a drug.

Sources and references: [3]

Know the symptoms that need early contact

Checkpoint inhibitors can cause inflammation in healthy organs, including the lungs, bowel, liver, skin and hormone-producing glands. Persistent diarrhea, new breathlessness, jaundice, marked weakness or unusual headaches should be reported promptly. Problems can appear even after treatment stops.

Keep the drug names and the oncology contact details with you. If you attend another hospital, tell the clinician that you have received immunotherapy. The team may need tests, a treatment pause and medicines to control inflammation depending on the organ and severity.

Sources and references: [3]

Understand the complete treatment burden

The chemotherapy partner brings additional side effects and laboratory checks. Ask which symptoms are expected from each part of the regimen and who will manage them. The planned duration can differ between early and advanced treatment.

Request a written calendar with infusions, blood tests, response assessment and surgery if relevant. Discuss fertility and practical support before treatment begins. If significant toxicity occurs, ask how the team will decide whether to restart, alter or stop the immunotherapy component.

Sources and references: [1] [3]

Preparing an immunotherapy consultation in Shanghai

Fudan University Shanghai Cancer Center has a breast cancer multidisciplinary service. A focused review can determine how a proposed immunotherapy regimen fits the stage, receptor profile and previous treatment.

EastMedGo can help organize the inquiry with pathology, PD-L1 results, scans and any autoimmune history. We can clarify records and appointment logistics, with coordination costs explained separately. Include whether you are deciding on initial treatment or managing an adverse effect so the service can direct the review appropriately.

Sources and references: [4]

Common questions